抗病毒治疗乙型肝炎肝硬化的过去、现在和将来

doi:10.3969/j.issn.1672-5069.2015.05.002

实用肝脏病杂志 ›› 2015, Vol. 18 ›› Issue (5): 453-456.doi: 10.3969/j.issn.1672-5069.2015.05.002

抗病毒治疗乙型肝炎肝硬化的过去、现在和将来

韩莹，丁惠国

100069 北京市首都医科大学附属北京佑安医院肝病消化中心

收稿日期:2015-06-30 出版日期:2015-09-10 发布日期:2016-02-18
通讯作者: 丁惠国，E-mail:dinghuiguo@medmail.com.cn E-mail:gladyshanying@163.com
作者简介:韩莹：女，37岁，博士研究生，副主任医师。研究方向：肝脏病学。E-mail: gladyshanying@163.com

Antiviral therapy of patients with hepatitis B-induced liver cirrhosis:The past, present and future

Han Ying，Ding Huiguo

Department of Gastroenterology and Hepatology，Youan Hospital Affiliated to Capital Medical University，Beijing 100069

Received:2015-06-30 Online:2015-09-10 Published:2016-02-18

摘要/Abstract

关键词: 慢性乙型肝炎, 肝硬化, 核苷（酸）类似物, 预后

Key words: Hepatitis B, Cirrhosis, Nucleos（t）ide analogue, Prognosis

韩莹，丁惠国. 抗病毒治疗乙型肝炎肝硬化的过去、现在和将来[J]. 实用肝脏病杂志, 2015, 18(5): 453-456.

Han Ying，Ding Huiguo. Antiviral therapy of patients with hepatitis B-induced liver cirrhosis:The past, present and future[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 453-456.

[1] Vallet-Pichard A，Mallet V，Costentin CE，et al. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther，2009，7（5）:527-535.
[2] Xu B，Xu GG，Guo Q，et al. Long term treatment of lamivudine in chronic hepatitis B patients with severe liver fibrosis-ten-year follow-up outcomes of NUCB 4006 trial. Chin J Infect Dis，2010，28（11）:656-661.
[3] Chang TT，Liaw YF，Wu SS，et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology，2010，52（3）:886-893.
[4] Fink SA，Jacobson IM. Managing patients with hepatitis B-related or hepatitis C-related decompensated cirrhosis. Nat Rev Gastroenterol Hepatol，2011，8（5）:285-295.
[5] Manolakopoulos S，Triantos C，Theodoropoulos J，et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol，2009，51（3）:468-474.
[6] Zhang QQ，An X，Liu YH，et al. Long-term nucleos（t）ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications:a meta-analysis. Virol J，2011，15（8）:72.
[7] Li CZ，Cheng LF，Li QS，et al. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol，2013，19:6849-6856.
[8] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol，2012，57（1）:167-185.
[9] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[10] Vallet-Pichard A，Mallet V，Costentin CE，et al. Treatment of HBV-related cirrhosis.Expert Rev Anti Infect Ther，2009，7（5）:527-535.
[11] Shin SK，Kim JH，Park H，et al. Improvement of liver function and non-invasive fibrosis markers in hepatitis B virus-associated cirrhosis:2 years of entecavir treatment. J Gastroenterol Hepatol，2015，Jun 11. doi:10.1111/jgh.13020. [Epub ahead of print]. [12] Liaw YF，Sung JJ，Chow WC，et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med，2004，351（15）:1521-1531.
[13] Perrillo RP，Wright T，Rakela J，et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology，2001，33（2）:424-432.
[14] Schiff E，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl，2007，13（3）:349-360.
[15] Schiff ER，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients.Hepatology，2003，38（6）:1419-1427.
[16] Wong GL，Chan HL，Mak CW，et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology，2013，58（5）:1537-1547.
[17] Shim JH，Lee HC，Kim KM，et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.J Hepatol，2010，52（2）:176-182.
[18] Chan HL，Chen YC，Gane EJ，et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat，2012，19（10）:732-743.
[19] Gane EJ，Deray G. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology，2014，146（1）:138-146.
[20] Koklü S，Tuna Y，Gülsen MT， et al. Long-term efficacy and safety of lamivudine，entecavir，and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol，2013，11（1）:88-94.
[21] Marcellin P，Buti M，Gane EJ，et al. Five years of treatment with tenofovir DF （TDF） for chronic hepatitis B（CHB） infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology，2011，54（Suppl）:1011A.
[22] Liaw YF，Gane E，Leung N，et al. GLOBE Study Group. 2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B.Gastroenterology，2009，136（2）:486-495.
[23] 任江波，王宇，李红艺，等．替比夫定治疗慢性乙型肝炎期间肌酸激酶升高的观察与分析．中华肝脏病杂志，2012；20（9）:641-643.
[24] Jung YK，Yeon JE，Choi JH，et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver，2010，4（3）:389-393.
[25] Pol S，Lampertico P.First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings:from clinical trials to clinical practice. J Viral Hepat，2012，19（6）:377-386.

抗病毒治疗乙型肝炎肝硬化的过去、现在和将来

Antiviral therapy of patients with hepatitis B-induced liver cirrhosis:The past, present and future

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[7]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[8]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[11]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[12]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[13]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[14]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[15]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.